AC Immune (NASDAQ:ACIU) received a $8.00 price target from HC Wainwright in a research note issued to investors on Friday, TipRanks reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 48.15% from the stock’s previous close.
Several other equities research analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Wix.Com from a “hold” rating to a “sell” rating in a research note on Monday, April 8th. ValuEngine downgraded shares of Welbilt from a “hold” rating to a “sell” rating in a research note on Wednesday, June 12th. Finally, BidaskClub downgraded shares of Xencor from a “sell” rating to a “strong sell” rating in a research note on Tuesday, June 11th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $11.94.
ACIU stock traded up $0.11 during midday trading on Friday, hitting $5.40. 197,358 shares of the company traded hands, compared to its average volume of 72,756. AC Immune has a twelve month low of $3.25 and a twelve month high of $17.40. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.01. The firm’s 50 day simple moving average is $5.35. The company has a market cap of $364.83 million, a PE ratio of -6.59 and a beta of 0.02.
AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Wednesday, May 15th. The company reported $0.84 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.36). AC Immune had a net margin of 29.66% and a return on equity of 12.17%. The company had revenue of $75.28 million for the quarter, compared to analyst estimates of $106.81 million. Research analysts anticipate that AC Immune will post 0.17 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in the company. FMR LLC grew its stake in shares of AC Immune by 7.7% in the fourth quarter. FMR LLC now owns 5,612,759 shares of the company’s stock worth $53,039,000 after acquiring an additional 403,086 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of AC Immune in the fourth quarter worth $6,092,000. Artisan Partners Limited Partnership acquired a new stake in shares of AC Immune in the first quarter worth $903,000. Alps Advisors Inc. grew its stake in shares of AC Immune by 4.5% in the first quarter. Alps Advisors Inc. now owns 162,707 shares of the company’s stock worth $822,000 after acquiring an additional 7,029 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of AC Immune in the first quarter worth $397,000. Institutional investors and hedge funds own 26.54% of the company’s stock.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Further Reading: What is a stock buyback?
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.